Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APT-1011 in Eosinophilic Esophagitis
NCT03191864Phase 2Completed
- Sponsor
- Adare Pharma Solutions
- Start
- Jun 2017
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of EPI-EE in eosinophilic esophagitis (EoE) (5 arms), sponsored by Adare Pharma Solutions. Primary endpoint: Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) at 12 weeks. Started Jun 2017; status: completed.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT03191864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191864.